Resistance to receptor-blocking therapies primes tumors as targets for HER3-homing nanobiologics.

ABSTRACT: Resistance to anti-tumor therapeutics is an important clinical problem. Tumor-targeted therapies currently used in the clinic are derived from antibodies or small molecules that mitigate growth factor activity. These have improved therapeutic efficacy and safety compared to traditional treatment modalities but resistance arises in the majority of clinical cases. Targeting such resistance could improve tumor abatement and patient survival. A growing number of such tumors are characterized by prominent expression of the human epidermal growth factor receptor 3 (HER3) on the cell surface. This study presents a "Trojan-Horse" approach to combating these tumors by using a receptor-targeted biocarrier that exploits the HER3 cell surface protein as a portal to sneak therapeutics into tumor cells

SUBMITTER: Sims JD 

PROVIDER: S-EPMC5807213 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature